Giant Cell Tumor Clinical Trials

1 recruiting

Giant Cell Tumor Trials at a Glance

11 actively recruiting trials for giant cell tumor are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Boston, Beijing, and Houston. Lead sponsors running giant cell tumor studies include Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Dana-Farber Cancer Institute, and Daiichi Sankyo.

Browse giant cell tumor trials by phase

Treatments under study

About Giant Cell Tumor Clinical Trials

Looking for clinical trials for Giant Cell Tumor? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Giant Cell Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Giant Cell Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 3

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Giant Cell Tumor of Bone
St. Louis University120 enrolled16 locationsNCT03295981
Recruiting
Phase 2

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

Tenosynovial Giant Cell Tumor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany20 enrolled1 locationNCT07499362
Recruiting
Phase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

NeoplasmsTenosynovial Giant Cell Tumor
Abbisko Therapeutics Co, Ltd276 enrolled17 locationsNCT04192344
Recruiting
Phase 4

Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery

Tenosynovial Giant Cell Tumor
Shanghai Jiao Tong University Affiliated Sixth People's Hospital40 enrolled1 locationNCT07315841
Recruiting
Phase 4

Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery

Giant Cell Tumor of Bone
Shanghai Jiao Tong University Affiliated Sixth People's Hospital40 enrolled1 locationNCT07315828
Recruiting

PROMIS and Mobility Evaluation in Sarcoma Patients

SarcomaGiant Cell Tumor of Bone
University of Calgary800 enrolled4 locationsNCT07227961
Recruiting

Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals, LLC100 enrolled1 locationNCT07075471
Recruiting

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

HepatotoxicityTenosynovial Giant Cell Tumor
Daiichi Sankyo30 enrolled8 locationsNCT04635111
Recruiting

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Lung CancerCancer RiskCancer Predisposition Syndrome+28 more
Dana-Farber Cancer Institute5,000 enrolled1 locationNCT05463796
Recruiting
Phase 1Phase 2

Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study

Giant Cell Tumor of Bone
Tang Xiaodong45 enrolled1 locationNCT06647901
Recruiting
Phase 2

Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage

Giant Cell Tumor of Bone
Second Affiliated Hospital, School of Medicine, Zhejiang University153 enrolled1 locationNCT05595603